CLTEF Stock - Calliditas Therapeutics AB (publ)
Unlock GoAI Insights for CLTEF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $18,209 | $1.21B | $802.88M | $229.35M | $874,000 |
| Gross Profit | $-10,155 | $1.15B | $75.49M | $229.35M | $874,000 |
| Gross Margin | -55.8% | 95.0% | 9.4% | 100.0% | 100.0% |
| Operating Income | $-207,290 | $-373,055,000 | $-421,943,000 | $-524,456,000 | $-379,720,000 |
| Net Income | $-101,711 | $-466,185,000 | $-39,513,722 | $-55,306,294 | $-52,692,777 |
| Net Margin | -558.6% | -38.6% | -4.9% | -24.1% | -6028.9% |
| EPS | $-0.06 | $-8.69 | $-7.78 | $-9.84 | $-9.66 |
Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy. The company's lead product candidate is Setanaxib, a NOX inhibitor that is in Phase 2b/3 clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for type 1 diabetic kidney disease. It also develops Budenofalk 3 mg oral capsules for the treatment of autoimmune hepatitis. The company was incorporated in 2004 and is headquartered in Stockholm, Sweden.
Visit WebsiteEarnings History & Surprises
CLTEFEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q3 2023 | Sep 30, 2023 | — | $-0.03 | — | — |
Q2 2023 | Jun 30, 2023 | — | $-0.01 | — | — |
Q1 2023 | Mar 31, 2023 | — | $-0.03 | — | — |
Q1 2023 | Feb 23, 2023 | $-1.71 | $-0.07 | +95.9% | ✓ BEAT |
Q4 2022 | Nov 14, 2022 | $-3.02 | $-0.17 | +94.4% | ✓ BEAT |
Q3 2022 | Aug 18, 2022 | $-4.23 | $-3.62 | +14.4% | ✓ BEAT |
Q2 2022 | May 18, 2022 | — | $-3.95 | — | — |
Q1 2022 | Feb 24, 2022 | $-3.72 | $-4.19 | -12.6% | ✗ MISS |
Q4 2021 | Nov 18, 2021 | — | $0.21 | — | — |
Q3 2021 | Aug 19, 2021 | — | $-3.20 | — | — |
Q2 2021 | May 18, 2021 | — | $-2.51 | — | — |
Q1 2021 | Feb 18, 2021 | — | $-0.05 | — | — |
Q4 2020 | Nov 12, 2020 | — | $-0.03 | — | — |
Q3 2020 | Aug 13, 2020 | — | $-0.02 | — | — |
Q2 2020 | May 14, 2020 | — | $-0.02 | — | — |
Q1 2020 | Feb 14, 2020 | — | $-0.01 | — | — |
Q4 2019 | Nov 14, 2019 | — | $-0.01 | — | — |
Q3 2019 | Aug 15, 2019 | — | $0.03 | — | — |
Q2 2019 | May 8, 2019 | — | $-0.01 | — | — |
Q1 2019 | Feb 7, 2019 | — | $-0.02 | — | — |
Latest News
Frequently Asked Questions about CLTEF
What is CLTEF's current stock price?
What is the analyst price target for CLTEF?
What sector is Calliditas Therapeutics AB (publ) in?
What is CLTEF's market cap?
Does CLTEF pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to CLTEF for comparison